Intelliject
CRT/tanaka is working with the specialty pharmaceutical provider Intelliject to educate key audiences about the company’s four technology platforms and its lead product in development, the EpiCard. The EpiCard is a credit card sized auto-injector with a built-in voice chip that dictates step-by-step instructions for giving an epinephrine shot to someone having a severe allergic reaction. CRT/tanaka has conducted one-on-one meetings with allergists and pediatricians to support Intelliject’s efforts in positioning the EpiCard, assessing its business potential and evaluating its commercial partnership opportunities. The agency also assists Intelliject’s investor outreach and media relations activities, and has helped the company secure coverage in key medical device industry newsletters and blogs.
